CSL Behring Receives FDA Approval to Extend Shelf Life for Privigen(R) from 24 to 36 Months

Monday, April 19, 2010 General News
Email Print This Page Comment
Font : A-A+

Increases convenience, ease of use for primary immunodeficiency patients and health providers

Contact:

Greg Healy, Senior Manager, Communications & Public Relations

U.S. Commercial Operations

CSL Behring

610-878-4841

Greg.Healy@cslbehring.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook